Biotech

All Articles

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our summary of notable management hirings, firings as we...

Lykos will definitely ask FDA to reassess its own selection adhering to rejection of MDMA therapy for post-traumatic stress disorder

.Adhering to a bad showing for Lykos Therapeutics' MDMA candidate for trauma at a recent FDA advisor...

AN 2 halves roll call, quits period 3 test after data dissatisfy

.AN2 Therapeutics is actually rethinking its own business in response to dull midphase records, swea...

Merck pays out $700M for bispecific, spying autoimmune position and possibility to test Amgen in cancer

.Merck &amp Co. is spending $700 million upfront to test Amgen in a blood cancer cells market. The p...

Gilead pays J&ampJ $320M to exit licensing package for seladelpar

.With Gilead Sciences about to an FDA choice for its liver ailment drug seladelpar, the business has...

' All hands on deck' at Lilly as peers target excessive weight market

.CEO David Ricks can easily observe the firms establishing tents at basecamp responsible for Eli Lil...

Entero laying off personnel, abandoning workplace and also stopping briefly R&ampD

.Bed Liquidators has actually transformed Entero Therapeutics white colored as a sheet. The financia...

Exelixis drops ADC after deciding it's no match for Tivdak

.Exelixis is quiting on its cells factor (TF)- targeting antibody-drug conjugate after ending the pr...

Relay dislikes SHP2 inhibitor after Genentech leaves

.3 full weeks after Roche's Genentech system bowed out an SHP2 prevention deal, Relay Therapeutics h...

Stoke's Dravet disorder med discharged of predisposed professional hold

.Stoke Therapies' Dravet disorder medicine has actually been freed from a predisposed hold, getting ...